HRP20202066T1 - Jednolančani oligonukleotidi za uporabu u medicinskom liječenju poremećaja kože - Google Patents
Jednolančani oligonukleotidi za uporabu u medicinskom liječenju poremećaja kože Download PDFInfo
- Publication number
- HRP20202066T1 HRP20202066T1 HRP20202066TT HRP20202066T HRP20202066T1 HR P20202066 T1 HRP20202066 T1 HR P20202066T1 HR P20202066T T HRP20202066T T HR P20202066TT HR P20202066 T HRP20202066 T HR P20202066T HR P20202066 T1 HRP20202066 T1 HR P20202066T1
- Authority
- HR
- Croatia
- Prior art keywords
- sson
- use according
- internucleotide linkages
- phosphorothioate internucleotide
- seq
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims 3
- 208000017520 skin disease Diseases 0.000 title claims 3
- 238000011282 treatment Methods 0.000 title claims 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 208000030962 Subcutaneous tissue disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- STGXGJRRAJKJRG-JDJSBBGDSA-N (3r,4r,5r)-5-(hydroxymethyl)-3-methoxyoxolane-2,4-diol Chemical compound CO[C@H]1C(O)O[C@H](CO)[C@H]1O STGXGJRRAJKJRG-JDJSBBGDSA-N 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000003908 antipruritic agent Substances 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Jednolančani oligonukleotid (ssON) za uporabu u liječenju ili profilaksi poremećaja kože i/ili potkožnog tkiva, uključujući pruritus,
naznačen time, što:
(a) dužina navedenog ssON je između 25 i 70 nukleotida;
(b) ili (i) najmanje 90% internukleotidnih veza u navedenom ssON su fosforotioatne internukleotidne veze; ili (ii) navedeni ssON sadrži najmanje četiri fosforotioatne internukleotidne veze i najmanje četiri 2’-O-metil modifikacije; i
(c) navedeni ssON ne sadrži nijedan CpG motiv.
2. Jednolančani oligonukleotid (ssON), naznačen time, što navedeni ssON sadrži nukleotidnu sekvencu predstavljenu sekvencom SEQ ID NO: 15 ili 16; pod uvjetom da ssON nema sekvencu predstavljenu sekvencom SEQ ID NO: 2, i gdje:
(a) dužina navedenog ssON je između 25 i 70 nukleotida;
(b) ili (i) najmanje 90% internukleotidnih veza u navedenom ssON su fosforotioatne internukleotidne veze; ili (ii) navedeni ssON sadrži najmanje četiri fosforotioatne internukleotidne veze i najmanje četiri 2’-O-metil modifikacije; i
(c) navedeni ssON ne sadrži nijedan CpG motiv.
3. SsON za uporabu prema patentnom zahtjevu 1, ili ssON prema patentnom zahtjevu 2, naznačen time, što navedeni ssON sadrži najmanje šest fosforotioatnih internukleotidnih veza i najmanje šest 2’-O-metil modifikacija.
4. SsON za uporabu prema patentnom zahtjevu 1 ili 3, ili ssON prema patentnom zahtjevu 2 ili 3, naznačen time, što su sve internukleotidne veze u navedenom ssON fosforotioatne internukleotidne veze.
5. SsON za uporabu prema bilo kojem od patentnih zahtjeva 1, 3 do 4, ili ssON prema bilo kojem od patentnih zahtjeva 2 do 4, naznačen time, što je dužina navedenog ssON između 25 i 35 nukleotida.
6. SsON za uporabu prema bilo kojem od patentnih zahtjeva 1, 3 do 5, naznačen time, što u navedenom ssON nije komplementarno sa bilo kojom ljudskom sekvencom iRNK više od 16 uzastopnih nukleotida i/ili gdje navedeni ssON nije samokomplementaran.
7. SsON za uporabu prema bilo kojem od patentnih zahtjeva 1, 3 do 6, ili ssON prema bilo kojem od patentnih zahtjeva 2 do 5, naznačen time, što su monosaharidi u navedenom ssON izabrani iz grupe koja se sastoji od 2’-deoksiriboze i 2’-O-metilriboze.
8. SsON za uporabu prema patentnom zahtjevu 7, naznačen time, što navedeni ssON sadrži sekvencu predstavljenu sekvencom SEQ ID NO: 2, 12, 13, 14, 15, 16, ili 19.
9. SsON za uporabu prema bilo kojem od patentnih zahtjeva 1, 3 do 8, naznačen time, što navedeni poremećaj uključuje dermatitis i/ili ekcem, i na primjer predstavlja atopijski dermatitis, i/ili gdje navedeni poremećaj uključuje pruritus.
10. SsON za uporabu prema bilo kojem od patentnih zahtjeva 1, 3 do 9, naznačen time, što je infekcija povezana sa navedenim poremećajem kože i/ili potkožnog tkiva.
11. SsON za uporabu prema bilo kojem od patentnih zahtjeva 1, 3 do 10, naznačen time, što se navedeni ssON koristi u kombinaciji sa anti-inflamatornim ili anti-pruritusnim sredstvom.
12. SsON za uporabu prema bilo kojem od patentnih zahtjeva 1, 3 do 11 kod ljudskog subjekta.
13. SsON prema bilo kojem od patentnih zahtjeva 2 do 5 i 7, naznačen time, što navedeni ssON ima nukleotidnu sekvencu predstavljenu sekvencom SEQ ID NO: 12, 13, 14, 15, 16, ili 19.
14. SsON prema bilo kojem od patentnih zahtjeva 2 do 5, 7 i 13 za uporabu u terapiji.
15. Farmaceutski pripravak koji sadrži ssON prema bilo kojem od patentnih zahtjeva 2 do 5, 7, 13 do 14, zajedno sa farmaceutski prihvatljivim nosačem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1550814 | 2015-06-15 | ||
| EP16734570.1A EP3307277B1 (en) | 2015-06-15 | 2016-06-14 | Single-stranded oligonucleotides for use in the medical treatment of skin disorders |
| PCT/EP2016/063596 WO2016202779A1 (en) | 2015-06-15 | 2016-06-14 | Single-stranded oligonucleotides for use in the medical treatment of skin disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20202066T1 true HRP20202066T1 (hr) | 2021-04-30 |
Family
ID=56345083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20202066TT HRP20202066T1 (hr) | 2015-06-15 | 2020-12-24 | Jednolančani oligonukleotidi za uporabu u medicinskom liječenju poremećaja kože |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10626401B2 (hr) |
| EP (1) | EP3307277B1 (hr) |
| AU (1) | AU2016280663B2 (hr) |
| CA (1) | CA2989371C (hr) |
| CY (1) | CY1123639T1 (hr) |
| DK (1) | DK3307277T3 (hr) |
| ES (1) | ES2834906T3 (hr) |
| HR (1) | HRP20202066T1 (hr) |
| HU (1) | HUE051875T2 (hr) |
| LT (1) | LT3307277T (hr) |
| PL (1) | PL3307277T3 (hr) |
| PT (1) | PT3307277T (hr) |
| RS (1) | RS61274B1 (hr) |
| SI (1) | SI3307277T1 (hr) |
| WO (1) | WO2016202779A1 (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201504124D0 (en) | 2015-03-11 | 2015-04-22 | Proqr Therapeutics B V | Oligonucleotides |
| EA036393B1 (ru) | 2015-05-21 | 2020-11-05 | Вингс Терапьютикс, Инк. | Антисмысловые олигонуклеотиды для лечения дистрофического буллезного эпидермолиза |
| GB201714330D0 (en) * | 2017-09-06 | 2017-10-18 | Järver Peter | Oligonucleotides |
| WO2019199720A1 (en) * | 2018-04-09 | 2019-10-17 | The Trustees Of Princeton University | Compositions comprising immune system activators and method of using same |
| WO2022229350A2 (en) | 2021-04-30 | 2022-11-03 | Tirmed Pharma Ab | Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
| US8101345B1 (en) * | 2005-03-25 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Proinflammatory nucleic acids |
| WO2008147956A2 (en) | 2007-05-25 | 2008-12-04 | Centocor, Inc. | Toll-like receptor 3 modulators and uses thereof |
| US20100040576A1 (en) | 2007-12-18 | 2010-02-18 | The Texas A&M University System | Modified Oligonucleotides For The Treatment Of Hepatitis C Infection |
-
2016
- 2016-06-14 US US15/736,020 patent/US10626401B2/en active Active
- 2016-06-14 HU HUE16734570A patent/HUE051875T2/hu unknown
- 2016-06-14 DK DK16734570.1T patent/DK3307277T3/da active
- 2016-06-14 PT PT167345701T patent/PT3307277T/pt unknown
- 2016-06-14 EP EP16734570.1A patent/EP3307277B1/en active Active
- 2016-06-14 SI SI201631042T patent/SI3307277T1/sl unknown
- 2016-06-14 WO PCT/EP2016/063596 patent/WO2016202779A1/en active Application Filing
- 2016-06-14 ES ES16734570T patent/ES2834906T3/es active Active
- 2016-06-14 AU AU2016280663A patent/AU2016280663B2/en active Active
- 2016-06-14 RS RS20201558A patent/RS61274B1/sr unknown
- 2016-06-14 PL PL16734570T patent/PL3307277T3/pl unknown
- 2016-06-14 LT LTEP16734570.1T patent/LT3307277T/lt unknown
- 2016-06-14 CA CA2989371A patent/CA2989371C/en active Active
-
2020
- 2020-12-21 CY CY20201101204T patent/CY1123639T1/el unknown
- 2020-12-24 HR HRP20202066TT patent/HRP20202066T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016280663B2 (en) | 2021-04-29 |
| PT3307277T (pt) | 2020-12-30 |
| HUE051875T2 (hu) | 2021-04-28 |
| SI3307277T1 (sl) | 2021-02-26 |
| DK3307277T3 (da) | 2020-12-07 |
| PL3307277T3 (pl) | 2021-03-08 |
| EP3307277A1 (en) | 2018-04-18 |
| WO2016202779A1 (en) | 2016-12-22 |
| US20180142246A1 (en) | 2018-05-24 |
| ES2834906T3 (es) | 2021-06-21 |
| CA2989371A1 (en) | 2016-12-22 |
| RS61274B1 (sr) | 2021-01-29 |
| CA2989371C (en) | 2024-02-06 |
| CY1123639T1 (el) | 2022-03-24 |
| US10626401B2 (en) | 2020-04-21 |
| EP3307277B1 (en) | 2020-10-07 |
| AU2016280663A1 (en) | 2018-01-18 |
| LT3307277T (lt) | 2020-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20202066T1 (hr) | Jednolančani oligonukleotidi za uporabu u medicinskom liječenju poremećaja kože | |
| MX2017002144A (es) | Agentes de ácido ribonucleico (arn) de cadena doble modificados. | |
| JP2013226147A5 (hr) | ||
| MX2023010958A (es) | Agentes de arn modificados con efecto reducido fuera de la diana. | |
| AR084319A1 (es) | INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS | |
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| WO2013074974A3 (en) | Modified rnai agents | |
| ZA202211060B (en) | Anti-viral compounds and methods for administration thereof | |
| MX2010009195A (es) | Rnas ultrapequeños como antagonistas del receptor tipo toll-3. | |
| MX2024001181A (es) | Oligomeros antisentido y metodos de uso de los mismos para el tratamiento de enfermedades asociadas con el gen alfa-glucosidasa acida. | |
| HRP20191723T1 (hr) | Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa | |
| BR112019008810A2 (pt) | micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer | |
| MX2021009135A (es) | Oligonucleotidos que igualan exon 73 de col7a1 para terapia de epidermolisis bullosa. | |
| MD4760C8 (ro) | Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D | |
| PE20211749A1 (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos | |
| JP2015504438A5 (hr) | ||
| BR112022002690A2 (pt) | Construtos de vesícula-aso extracelular tendo como alvo cebp/beta | |
| JP2011515357A5 (hr) | ||
| BR112017013765A2 (pt) | métodos para uso de oligonucleotídeos antisense smad7 | |
| BR112013006541A2 (pt) | agente preventivo ou terapêutico para fibrose | |
| HRP20220999T1 (hr) | Terapija za ulcerozni kolitis zasnovana na oligonukleotidu | |
| BR112018010736A2 (pt) | oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos | |
| AR123679A1 (es) | COMPOSICIONES DE ARNi CONTRA EL GEN SNCA Y MÉTODOS DE USO DE LAS MISMAS PARA TRATAR O PREVENIR ENFERMEDADES NEURODEGENERATIVAS ASOCIADAS CON SNCA | |
| WO2017078526A3 (en) | Antisense oligonucleotide-mediated exon skipping as systemic therapy for recessive dystrophic epidermolysis bullosa (rdeb). |